Clinical Trials Directory

Trials / Conditions / Recurrent Platinum-Resistant Ovarian Carcinoma

Recurrent Platinum-Resistant Ovarian Carcinoma

12 registered clinical trials studyying Recurrent Platinum-Resistant Ovarian Carcinoma — 5 currently recruiting.

StatusTrialSponsorPhase
WithdrawnTesting the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without B
NCT06393751
National Cancer Institute (NCI)Phase 1 / Phase 2
RecruitingDT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT06964009
Elizabeth Stover, MD, PhDPhase 1
RecruitingMUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT06483048
Mayo ClinicPhase 1
RecruitingPembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patien
NCT05231122
Roswell Park Cancer InstitutePhase 2
RecruitingTesting Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovaria
NCT05950464
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTesting the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT05691504
National Cancer Institute (NCI)Phase 1
WithdrawnComparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent
NCT05295589
National Cancer Institute (NCI)Phase 2
SuspendedTesting the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
NCT04840589
National Cancer Institute (NCI)Phase 1
RecruitingTesting the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT04633239
National Cancer Institute (NCI)Phase 1
Active Not RecruitingComparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800
National Cancer Institute (NCI)Phase 2
Active Not RecruitingP53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Ca
NCT03113487
City of Hope Medical CenterPhase 2
Active Not RecruitingPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R
NCT02839707
National Cancer Institute (NCI)Phase 2 / Phase 3